The National Blood Centre (NBC) has announced that it will sell its remaining supply of plasma to open competition to maximize its utility for public health. Pharmaceutical manufacturers from across Europe are participating in the procurement process. Medical professionals utilize plasma derived from blood to treat various serious and life-threatening medical conditions.
The plasma is processed into specific preparations, each designed for distinct therapeutic uses. For instance, albumin is a critical component used in the treatment of patients suffering from severe burns, major injuries, or advanced liver diseases. Another vital preparation is immunoglobulins, which are administered to treat immunodeficiency disorders and certain neurological conditions.
Furthermore, blood clotting factors are essential for individuals managing hemophilia and other types of coagulation disorders. The demand for these derived products underscores the medical importance of the resource. To provide context on the scale of utilization, the NBC reported that in 2024, 28,000 liters of plasma were sold for the production of pharmaceutical preparations.
Looking ahead, the Centre estimates that in 2025, approximately 21,000 liters of plasma are projected to be sold, highlighting the consistent need for these blood-derived treatments. This ongoing commercial sale ensures that the necessary components remain available to support complex medical treatments across the continent.
Topics: #blood #plasma #which
Last year, over 67,000 packets of blood plasma-derived medicines were distributed to hospitals and pharmacies across Lithuania. The National Blood Centre (NBC) has announced plans to sell its remainin
What is the process for determining the price of the plasma through open competition?